… Sims o … Sims is a full-time employee of Eli Lilly & Co. Maria Isaac is a full-time employee of
the European Medicines Agency. Lisa J. … Chertkow, BT Hyman, CR Jack Jr., CH Kawas, et al. …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess
efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid …

Background A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer’s disease have had mixed results. Methods We tested solanezumab, …

… SIMS … SIMS … SIMS …

With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies,
simple, widely available screening tests are needed to identify which individuals, who are …

The nuclear protein high-mobility group box 1 (HMGB-1) promotes inflammation in sepsis,
but little is known about its role in brain ischemia-induced inflammation. We report that HMGB-…

Calcium plays a central role in neuronal function and injury. Dantrolene, an inhibitor of the
ryanodine receptor, inhibits intracellular calcium release from the sarco-endoplasmic reticulum…

Background: Rapid and easy clinical assessments for volumes of infarction and perfusion
mismatch are needed. We tested whether simple geometric models generated accurate …